WebNov 16, 2024 · Patients who received cyclophosphamide with fludarabine (Cy-Flu) to deplete lymphoid cells prior to CART1 were more likely to exhibit enhanced CAR T cell expansion and persistence after CART2, and more likely to show therapeutic responses after CART2 infusion.They also had a lower risk of disease progression or death after … WebMultivariable analysis showed that preexisting neurologic comorbidities (p=0.0023), and factors associated with increased in vivo CAR-T cell numbers, including cyclophosphamide (Cy) and fludarabine (Flu) lymphodepletion (p=0.0259), higher infused CAR-T cell dose (p=0.0009), and higher burden of malignant CD19 + B cells in marrow (p=0.0165) were ...
Lymphodepletion followed by donor lymphocyte infusion (DLI
WebSep 6, 2024 · Cohort 1 received CART alone, cohort 2 received CARTs plus cyclophosphamide and fludarabine (Cy/Flu), and cohort 3 was treated with CARTs, … WebNov 24, 2024 · Left panel, probabilities of developing grade ≥3 CRS from a proportional odds model adjusting for Cy-Flu lymphodepletion and including two interaction terms (CAR T cell dose level [DL] and the ... the prima marina
Ligand-inducible, prostate stem cell antigen (PSCA)-directed …
WebNov 10, 2024 · One patient received bendamustine (benda) lymphodepletion before CD30.CAR-T cells at University of North Carolina (UNC), and 2 years later, received cyclophosphamide-fludarabine (cy-flu) lymphodepletion before CD30.CAR-T cells at Baylor College of Medicine (BCM). WebOct 1, 2007 · In Cy/Flu/DLI patients, T-cell proliferation was elevated at 14 days after DLI. Although these data suggest that chemotherapy-induced lymphodepletion enhances activation of donor lymphocytes, the toxicity needs to be managed before testing whether better disease control can be achieved. WebApr 22, 2024 · This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are … the primarchs mother